|Bid||186.80 x 800|
|Ask||188.88 x 800|
|Day's range||184.34 - 187.20|
|52-week range||176.36 - 242.99|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||24.67|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BOSTON, October 22, 2021--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
BOSTON, October 19, 2021--Vertex announced that five abstracts about its cystic fibrosis (CF) medicines will be presented at the 2021 North American Cystic Fibrosis Conference.
BOSTON, October 18, 2021--Vertex today announced positive data for the first patient from the Phase 1/2 clinical trial of VX-880, for the treatment of type-1 diabetes.